title: A signature for immune response correlates with HCV treatment outcome in Caucasian subjects.
abstract: This data article contains Supplementary material for a published research article describing a whole-blood proteomic signature that predicts treatment outcome for subjects infected with hepatitis C virus (HCV) [1]. The proteomic signature is derived from whole-blood samples from subjects infected with HCV. The article includes detailed experimental and computational methods used in the analysis. The article also includes tables of demographic and other information about the subjects. Finally, the article includes several figures and tables showing detailed results of the analyses (e.g. lists of identified proteins and coefficients/ROC curves for the regression models).
authors.affiliation: Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Hare
authors.affiliation: Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
authors.forename: Eric
authors.initials: E
authors.lastname: Haseltine
authors.affiliation: Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Fleming
authors.affiliation: Caprion Proteomics, Montreal, Quebec, Canada H2X 3Y7.
authors.forename: Daniel
authors.initials: D
authors.lastname: Chelsky
authors.affiliation: Caprion Proteomics, Montreal, Quebec, Canada H2X 3Y7.
authors.forename: Laura
authors.initials: L
authors.lastname: McIntosh
authors.affiliation: Caprion Proteomics, Montreal, Quebec, Canada H2X 3Y7.
authors.forename: Rene
authors.initials: R
authors.lastname: Allard
authors.affiliation: Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
authors.forename: Martyn
authors.initials: M
authors.lastname: Botfield